Published in J Lipid Res on December 20, 2006
Three-dimensional models of HDL apoA-I: implications for its assembly and function. J Lipid Res (2008) 1.47
Circulating Nef induces dyslipidemia in simian immunodeficiency virus-infected macaques by suppressing cholesterol efflux. J Infect Dis (2010) 1.34
HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev Cardiovasc Ther (2008) 1.30
Inflammation modulates human HDL composition and function in vivo. Atherosclerosis (2012) 1.18
High Density Lipoprotein and it's Dysfunction. Open Biochem J (2012) 1.17
Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women. J Lipid Res (2010) 1.16
Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res (2009) 1.08
Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. Biochim Biophys Acta (2009) 0.96
Activation of lecithin:cholesterol acyltransferase by HDL ApoA-I central helices. Clin Lipidol (2009) 0.92
Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Thromb Vasc Biol (2008) 0.92
ApoE and ApoC-I polymorphisms: association of genotype with cardiovascular disease phenotype in African Americans. J Lipid Res (2009) 0.91
Lecithin: cholesterol acyltransferase and atherosclerosis: another high-density lipoprotein story that doesn't quite follow the script. Circulation (2009) 0.91
Complexities of plasma apolipoprotein C-III metabolism. J Lipid Res (2011) 0.91
Short communication: effects of omega-3 fatty acids on triglycerides and high-density lipoprotein subprofiles in HIV-infected persons with hypertriglyceridemia. AIDS Res Hum Retroviruses (2014) 0.87
Factors controlling nascent high-density lipoprotein particle heterogeneity: ATP-binding cassette transporter A1 activity and cell lipid and apolipoprotein AI availability. FASEB J (2013) 0.87
Evidence for the presence of lipid-free monomolecular apolipoprotein A-1 in plasma. J Lipid Res (2013) 0.86
Speciated human high-density lipoprotein protein proximity profiles. Biochemistry (2010) 0.86
Mass spectrometric determination of apolipoprotein molecular stoichiometry in reconstituted high density lipoprotein particles. J Lipid Res (2009) 0.86
An ABCA1-independent pathway for recycling a poorly lipidated 8.1 nm apolipoprotein E particle from glia. J Lipid Res (2011) 0.86
LCAT synthesized by primary astrocytes esterifies cholesterol on glia-derived lipoproteins. J Lipid Res (2008) 0.86
Properties of the products formed by the activity of serum opacity factor against human plasma high-density lipoproteins. Chem Phys Lipids (2008) 0.84
The effects of sterol structure upon sterol esterification. Atherosclerosis (2009) 0.83
HDL deficiency due to a new insertion mutation (ApoA-INashua) and review of the literature. J Clin Lipidol (2012) 0.81
Homozygous lecithin:cholesterol acyltransferase (LCAT) deficiency due to a new loss of function mutation and review of the literature. J Clin Lipidol (2011) 0.81
Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease. J Lipid Res (2014) 0.79
Cardiovascular Disease-Risk Markers in HIV Patients. J AIDS Clin Res (2014) 0.78
Human serum preβ1-high density lipoprotein levels are independently and negatively associated with coronary artery diseases. Nutr Metab (Lond) (2016) 0.77
Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial. Atherosclerosis (2016) 0.77
Bioinformatic Analysis of Plasma Apolipoproteins A-I and A-II Revealed Unique Features of A-I/A-II HDL Particles in Human Plasma. Sci Rep (2016) 0.77
Lipid oxidation in carriers of lecithin:cholesterol acyltransferase gene mutations. Arterioscler Thromb Vasc Biol (2012) 0.77
Markers of Systemic Inflammation and Apo-AI Containing HDL Subpopulations in Women with and without Diabetes. Int J Endocrinol (2014) 0.77
Familial lecithin:cholesterol acyltransferase deficiency: First-in-human treatment with enzyme replacement. J Clin Lipidol (2015) 0.77
Lipoprotein X Causes Renal Disease in LCAT Deficiency. PLoS One (2016) 0.75
Solution structure of discoidal high-density lipoprotein particles with a shortened apolipoprotein A-I. Nat Struct Mol Biol (2016) 0.75
Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency. J Lipid Res (2017) 0.75
Detection and treatment of atherosclerosis using nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.75
High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency. Atherosclerosis (2016) 0.75
Association between lipids, lipoproteins composition of HDL particles and triglyceride-rich lipoproteins, and LCAT and CETP activity in post-renal transplant patients. Cell Biochem Biophys (2013) 0.75
Decreased high density lipoprotein cholesterol is an independent predictor for persistent organ failure, pancreatic necrosis and mortality in acute pancreatitis. Sci Rep (2017) 0.75
Design and implementation of microarray gene expression markup language (MAGE-ML). Genome Biol (2002) 16.75
Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA (2005) 9.61
Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35
A simple spreadsheet-based, MIAME-supportive format for microarray data: MAGE-TAB. BMC Bioinformatics (2006) 7.53
Retracted Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science (2004) 7.21
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest (2009) 7.09
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA (2007) 6.95
Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA (2002) 6.48
Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA (2003) 6.17
Pattern separation in the human hippocampal CA3 and dentate gyrus. Science (2008) 5.56
A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science (2008) 4.50
Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation (2006) 4.25
The first RSBI (ISA-TAB) workshop: "can a simple format work for complex studies?". OMICS (2008) 4.15
The Functional Genomics Experiment model (FuGE): an extensible framework for standards in functional genomics. Nat Biotechnol (2007) 3.55
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med (2004) 3.49
Direct care workers in the National Drug Abuse Treatment Clinical Trials Network: characteristics, opinions, and beliefs. Psychiatr Serv (2007) 3.38
Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol (2010) 2.78
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology (2003) 2.61
Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol (2005) 2.61
Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med (2002) 2.59
HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem (2011) 2.33
Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation (2005) 2.21
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol (2009) 2.19
Low-fat diets and weight change. JAMA (2006) 2.19
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
Organizational Readiness for Change and opinions toward treatment innovations. J Subst Abuse Treat (2007) 2.14
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11
Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol (2002) 2.07
Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin Chem (2004) 2.05
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study. Diabetes Care (2011) 2.00
High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol (2004) 2.00
The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction (2002) 1.94
Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis (2007) 1.93
Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler Thromb Vasc Biol (2006) 1.87
Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res (2005) 1.83
High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res (2003) 1.82
Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol (2004) 1.80
Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-alpha secretion in Abca1-deficient macrophages. J Lipid Res (2006) 1.73
Image-based estimation of ventricular fiber orientations for personalized modeling of cardiac electrophysiology. IEEE Trans Med Imaging (2012) 1.72
Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol (2004) 1.71
Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug Alcohol Depend (2007) 1.64
A chloroplast transgenic approach to hyper-express and purify Human Serum Albumin, a protein highly susceptible to proteolytic degradation. Plant Biotechnol J (2003) 1.64
Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem (2007) 1.64
Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order amish. Arch Intern Med (2010) 1.64
Deletion of progranulin exacerbates atherosclerosis in ApoE knockout mice. Cardiovasc Res (2013) 1.64
Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol (2005) 1.64
Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther (2003) 1.63
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol (2011) 1.60
Rising national prevalence of life-limiting conditions in children in England. Pediatrics (2012) 1.59
Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation (2009) 1.56
Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis (2006) 1.54
Trisodium citrate 46.7% selectively and safely reduces staphylococcal catheter-related bacteraemia. Nephrol Dial Transplant (2008) 1.52
Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol (2011) 1.52
High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol (2013) 1.50
Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects. Arterioscler Thromb Vasc Biol (2002) 1.50
ABCA1(Alabama): a novel variant associated with HDL deficiency and premature coronary artery disease. Atherosclerosis (2002) 1.49
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr (2013) 1.48
Retraction. Science (2007) 1.48
In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther (2007) 1.46
Recent Advances in Analytical Methods on Lipoprotein Subclasses: Calculation of Particle Numbers from Lipid Levels by Gel Permeation HPLC Using "Spherical Particle Model". J Oleo Sci (2016) 1.46
Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia. Cardiology (2011) 1.46
Patient satisfaction, prescription drug abuse, and potential unintended consequences. JAMA (2012) 1.45
Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol (2005) 1.43
Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem (2010) 1.43
The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease. J Mol Med (Berl) (2006) 1.42
Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. J Atheroscler Thromb (2013) 1.42
Resistance to chronic wasting disease in transgenic mice expressing a naturally occurring allelic variant of deer prion protein. J Virol (2007) 1.41
Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem (2001) 1.39
FuGE: Functional Genomics Experiment Object Model. OMICS (2006) 1.39
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol (2010) 1.36
The Oak Ridge Polycystic Kidney mouse: modeling ciliopathies of mice and men. Dev Dyn (2008) 1.36
Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol (2008) 1.35
Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care (2003) 1.35
Does glycemic variability impact mood and quality of life? Diabetes Technol Ther (2012) 1.35
Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the framingham study. J Clin Endocrinol Metab (2003) 1.35
Lead toxicity in a 14-year-old female with retained bullet fragments. Pediatrics (2006) 1.34
A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients. J Virol (2005) 1.32
Chromosomal location plays a role in regulation of aflatoxin gene expression in Aspergillus parasiticus. Appl Environ Microbiol (2002) 1.31
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology (2003) 1.31
Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis (2005) 1.30
Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD. J Lipid Res (2009) 1.29
Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. J Immunol Methods (2004) 1.29
ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J Lipid Res (2004) 1.28
Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol (2003) 1.28
Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther (2007) 1.28
Protective effects of fish intake and interactive effects of long-chain polyunsaturated fatty acid intakes on hip bone mineral density in older adults: the Framingham Osteoporosis Study. Am J Clin Nutr (2011) 1.26
Annotare--a tool for annotating high-throughput biomedical investigations and resulting data. Bioinformatics (2010) 1.26
Pathophysiology of human genetic CD36 deficiency. Trends Cardiovasc Med (2003) 1.25
Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol (2003) 1.25
Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol (2008) 1.25